Levetiracetam Use in Subarachnoid Hemorrhage
Levetiracetam is used for seizure prevention and treatment in patients with aneurysmal subarachnoid hemorrhage (aSAH), particularly in those with high-risk features such as ruptured MCA aneurysm, high-grade SAH, intracerebral hemorrhage, hydrocephalus, or cortical infarction. 1
Primary Indications
Seizure Prophylaxis in High-Risk Patients
Prophylactic use may be reasonable in patients with specific high-risk features:
- Ruptured middle cerebral artery (MCA) aneurysm
- High-grade SAH (Hunt-Hess grade ≥3)
- Intracerebral hemorrhage (ICH)
- Hydrocephalus
- Cortical infarction 1
Prophylaxis is NOT beneficial in patients without these high-risk features 1
Treatment of Acute Seizures
For patients presenting with seizures: Treatment with antiseizure medications for ≤7 days is reasonable to reduce seizure-related complications in the perioperative period 1
Beyond 7 days is not effective: In patients without prior epilepsy who present with seizures, continuing antiseizure medications beyond 7 days does not reduce future SAH-associated seizure risk 1
Why Levetiracetam Over Phenytoin
Levetiracetam has emerged as the preferred agent because phenytoin is associated with excess morbidity and mortality in aSAH patients 1. A single-blinded randomized study demonstrated that levetiracetam achieved the same seizure control as phenytoin but with significantly lower adverse effects as measured by Glasgow Outcome Scale-Extended and Disability Rating Scale 1.
The mechanism of phenytoin's harm may relate to metabolic competition with nimodipine (affecting delayed cerebral ischemia) or undiagnosed transaminase elevations 1. Research confirms levetiracetam's superior tolerability, with one study showing 39.8% of patients required switching from phenytoin to levetiracetam due to adverse events including elevated transaminases, thrombocytopenia, fever, rash, and worsening mental status 2.
Practical Dosing Considerations
While the FDA label indicates levetiracetam is approved for partial-onset seizures as adjunctive therapy 3, research in neurocritical care suggests dosing >1000 mg total daily dose (typically 1000 mg twice daily) may reduce seizure incidence compared to 500 mg twice daily in SAH and traumatic brain injury patients 4.
Important Caveats
Continuous EEG monitoring is reasonable in high-risk patients with fluctuating neurological examination or depressed mental state to detect subclinical seizures 1
Recent observational data raises concerns: Continuing ASMs in aSAH patients with EEG abnormalities was associated with lower likelihood of good functional outcomes, particularly with high-intensity treatment (high-dose single ASM, multiple ASMs, or anesthetics) 5. This suggests treatment should be targeted and time-limited rather than prolonged.
Duration matters: Most centers using prophylaxis administer levetiracetam for a mean of 13.2 days (median 11 days), though practice varies widely from 1 day to 6 weeks 6. The guideline-supported approach is ≤7 days for those presenting with seizures 1.
Routine prophylaxis for all patients is controversial: A 2024 study found no benefit to routine AED prophylaxis and noted significantly longer hospital stays and higher mortality in the prophylaxis group 7, supporting the 2023 AHA/ASA recommendation against universal prophylaxis 1.